These cell banks are necessary steps in the production of the cells to be encapsulated using the cell-in-a-Box technology for Nuvilex’s Phase IIb clinical trials in advanced, inoperable pancreatic cancer to be conducted in Australia.
Nuvilex CEO and president Kenneth L Waggoner noted that ViruSure has previous experience in handling the exact cell line that will be used in our Phase IIb clinical trials, which was a major factor in Nuvilex selecting ViruSure for this important step in our preparations for these trials.
"This decision was further supported by our on-site inspection of the ViruSure facilities and the excellent historical relationships between ViruSure’s key personnel with our partners at Austrianova. ViruSure has years of experience in producing and maintaining cell banks and is an industry leader in this arena," Waggoner added.
The cells that will make up the master, working and end of production cell banks will be those that convert the anticancer drug ifosfamide into its cancer-killing form. These therapeutic cells will be shipped to ViruSure for propagation.
First a Master Cell Bank will be established where aliquots of cells will be stored frozen. Cells from the Master Cell Bank will be propagated to make up the large number of cells that will comprise the Working Cell Bank.
Ultimately, cells from the Working Cell Bank will be encapsulated using the Cell-in-a-Box® live cell encapsulation technology. An End of Production Cell Bank will then be made from the final product for quality control purposes. The encapsulated cell product, together with ifosfamide, forms Nuvilex’s treatment for pancreatic cancer.